Raloxifene promotes adipocyte differentiation of 3T3-L1 cells

Eur J Pharmacol. 2006 May 24;538(1-3):1-4. doi: 10.1016/j.ejphar.2006.03.033. Epub 2006 Apr 27.

Abstract

To explore the possibility that raloxifene might influence an adipocyte differentiation and lipogenesis, we studied the effects of raloxifene on the expression of adiponectin and other peroxisome proliferator-activated receptor gamma targeting genes using the 3T3-L1 adipocytes. With standard adipogenic inducers, we added raloxifene at various doses for the adipocyte differentiation. Higher doses of raloxifene facilitated lipid accumulation of the 3T3-L1 cells. We next examined the differentiating and differentiated adipocytes and found that raloxifene augmented mRNA levels of adiponectin, adipocyte-specific fatty acid binding protein, and lipoprotein lipase dose-dependently in both. These effects were opposite those of 17beta-estradiol treatment. These findings suggest that raloxifene promotes adipocyte differentiation, providing a novel insight into the treatment of postmenopausal metabolic syndrome with hypoadiponectinemia.

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / cytology
  • Adipocytes / drug effects*
  • Adipocytes / metabolism
  • Adiponectin / genetics
  • Animals
  • Cell Differentiation / drug effects*
  • Dose-Response Relationship, Drug
  • Epoprostenol / metabolism
  • Estradiol / pharmacology
  • Estrogen Antagonists / pharmacology
  • Fatty Acid-Binding Proteins / genetics
  • Gene Expression / drug effects
  • Lipids / biosynthesis
  • Lipoprotein Lipase / genetics
  • Mice
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Raloxifene Hydrochloride / pharmacology*
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Adiponectin
  • Estrogen Antagonists
  • Fatty Acid-Binding Proteins
  • Lipids
  • RNA, Messenger
  • Raloxifene Hydrochloride
  • Estradiol
  • Epoprostenol
  • Lipoprotein Lipase